AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. AGEN
  4. [SCHEDULE 13G/A] Agenus Inc. SEC Filing

[SCHEDULE 13G/A] Agenus Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Filing content is currently unavailable.

Source:

Stock AGEN logo
Agenus

NASDAQ:AGEN

AGEN Rankings

#6230 Ranked by Market Cap
N/A Ranked by Dividends
#52 Top Loser

AGEN Latest News

Aug 11, 2025
Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress
Jul 31, 2025
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report
Jul 25, 2025
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025
Jul 17, 2025
US FDA Approves GSK’s SHINGRIX in a Prefilled Syringe Presentation
Jul 7, 2025
Agenus� BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

AGEN Latest SEC Filings

Aug 11, 2025
[8-K] Agenus Inc. Reports Material Event
Jul 29, 2025
[SCHEDULE 13G/A] Agenus Inc. SEC Filing
Jul 28, 2025
[Form 4] Agenus Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Agenus Inc. Insider Trading Activity
Jul 15, 2025
[Form 4] Agenus Inc. Insider Trading Activity

AGEN Stock Data

130.50M
26.88M
1.94%
33.79%
8.26%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
LEXINGTON